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I first wish to thank the American College of Epidemiology for this tribute to
Laboratory Markers in Epidemiological Research. I feel it is not so much a tribute to
me as to my predecessor and mentor, Dr. John R. Paul, who introduced me to the
concept and was a world leader in the field. Forty years ago, almost to this date, in
October 1946, I came to Yale to work on infectious mononucleosis under Dr. Paul at
theendof-my stint in theArmy in Japan. There I had thegood forhne to meetboth Dr.
Paul and Dr. Sabin in a trial ofJapanese B encephalitis vaccine they werecarrying out
in Okayama, where I happened to be stationed as a public health officer with the U.S.
Military Government team. It was 42 years ago, again almost to this date, that I was
first exposed to infectious mononucleosis at Carlisle Barracks, Pennsylvania. The
clinical disease appeared some four weeks later when I was stationed at Darnell
General Hospital in Kentucky, where it was attended by jaundice. It is thus a great
thrill for me to see the enormous strides made in understanding the etiology,
epidemiology, and pathogenesis of the disease since that time and the exciting new
developments in the molecular epidemiology of the virus, as unraveled by Dr. George
Miller, Ben Katz, and their group, with clinical and material input by Dr. James
Neiderman. The work bears continuing testimony to the contributions made to
infectious mononucleosis here at Yale, beginning with the discovery ofthe heterophile
antibody in 1932 by Drs. Paul and Bunnell, over 50 years ago.
Dr. Miller's presentation on the molecular epidemiology of Epstein-Barr virus
(EBV) provides eloquent evidenceofthe useofthese methods as highlyspecifictools to
identify the antigen and antibody in epidemiological studies, to understand the
virus-host relationship better, and toprovide a molecular basis for the useofvaccines. I
wish to discuss some of these issues and to raise questions concerning the possible
epidemiological and biological implications oftheir work.
First, as to thegenotypes, they haveshown thatusuallyonlyonegenotype is found in
multiple isolates from the same individual with infectious mononucleosis, but isolates
from different patients are different. Does such heterogeneity exist in close proximity
in nature, or are the patients geographically separate? Or is there only a parent wild
strain composed of several genotypes which separate out in the individual? Or does
only one wild genotype exist and the genotypic variation occur within each individual
in the course ofan infection? The fact that separate genotypes "breed true" on cloning
in the laboratory suggests that they may also do so in vivo.This finding may indicate
that the presence of separate genotypes actually represents double, simultaneous, or
sequential infections with distinct genotypes existing in nature. But why the hetero-
geneity? Perhaps the variation is minor. The issue is of considerable epidemiological
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TABLE 1
Epidemiological Uses of Genotypic Markers
1. Follow the pattern oftransmission.
A. Person to person
B. Mother to child
C. In clusters ofcases
2. Identify whether re-activation or re-infection occurs.
3. Determine whether long-term B-cell persistence is due to the same, different, or
multiple strains ofEBV.
4. Map geographic variation in genotype frequency in the U.S., Africa, and China
where different manifestations ofthe virus occur.
5. Determine whether multiply transfused patients yield multiple genotypes from
their B cells.
6. Establish whether the isolate from AIDS B-cell lymphomas is the same as in cir-
culating B cells or saliva.
significance. At the minimum, the tools for identifying genotypic variation provide a
powerful method to trace person-to-person spread and mother-to-child spread. It may
also permit one to find out who has been kissing whom. One must be careful ofkissing
persons with multiple salivary genotypes.
They have also shown that under unusual circumstances different genotypes may be
present in immunocompromised patients and occasionally even in normal individuals
with infectious mononucleosis. Since many ofus, including some epidemiologists, may
be frequently exposed to multiple strains ofEBV (assuming they exist in nature), then
the explanation ofmultiple genotypes in the same person may not be so much a matter
of exposure but more of the host response to multiple strains. It is also possible that
only one strain is involved, and that the rapid, uncontrolled multiplication occurring in
immunocompromised patients results in the emergence ofdifferent genotypes.
What aretheepidemiological usesoftheirfindings? Some areshown inTable 1. The
uses are primarily to identify whether an infection is caused by endogenous reactiva-
tion or toreinfection fromoutside, and todiscern person-to-person spread, especially in
clusters of cases. We know very little of the risk of a susceptible person kissing a
carrier, but the tools are at hand toexplore this specifically. Thediscovery ofgenotypic
variation also raises some important biologic questions, shown in Table 2. These have
to do with whether genotypic variation is ofsignificance in modulating the clinical and
immunological response, whether there are different oncogenic potentials associated
with genotypic variation, and whether a vaccine against one genotype will protect
against other genotypes. These are highly important issues.
Second, Dr. Miller has identified a sub-set of patients with the presumed diagnosis
ofchronic EBV infection in whom antibody to the BAM-K EBNA antigen is absent.
Some 18 percentofthe64 patients tested showed thisimmunological defectand almost
50 percent had either absent or low EBNA-1 titers with high antibody levels to
VCA-IgG and early antigen. It is welcome news indeed to find some type ofobjective
evidence of the ill-defined, mysterious, chronic mono syndrome. Perhaps other subtle
immunologic disorders will be identified in other patients. Their categorization of
symptoms into a severe, although less frequent, form, and one dominated by relentless
fatigue, also brings someorder into aconfusing clinical state. Thesearch for absenceto
BAM-K and other EBNA antibodies in concert with studies ofcell-mediated immun-
ity will be important in understanding the possible mechanisms ofthe syndrome.
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TABLE 2
Biologic Questions
1. Does genotypic variation affect the frequency or pattern ofthe host response to
EBV?
2. Dodifferent genotypes have different tissue tropisms or do they arise from multi-
plication in different tissues?
3. Dodifferent genotypes have different carcinogenic potential?
4. Is there cross-immunity between different genotypes or would a vaccine against
one genotype produce immunity to all genotypes?
In closing, I wish to thank the American College of Epidemiology again for
dedicating this part ofthe meeting to me; I thank the other contributors to the session
for their effort on my behalf, and I thank you all for the opportunity ofdiscussing the
exciting work that my associate Dr. Miller and his group are doing in molecular
biology.